We found that the aberrant integration of L1 retrotransposons has a relevant role in remodeling the architecture of the cancer genome in some human tumors, mainly by promoting megabase-scale deletions that, occasionally, generate genomic consequences that may promote cancer development through the removal of tumor-suppressor genes, such as CDKN2A, or trigger the amplification of oncogenes, such as CCND1. Here, CDKN2A is linked to neoplasm.